Barclays
SGMT icon

Barclays’s Sagimet Biosciences SGMT Stock Holding History

Barclays’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
227,931
+200,502
+731% +$1.36M ﹤0.01% 2425
2026
Q1 		$143K Sell
27,429
-1,909
-7% -$10.6K ﹤0.01% 3870
2025
Q4 		$174K Buy
29,338
+22,929
+358% +$165K ﹤0.01% 4396
2025
Q3 		$44K Buy
+6,409
New +$52K ﹤0.01% 4797
2025
Q2 		– Sell
-141
Closed -$460 – 5506
2025
Q1 		$460 Sell
141
-71
-33% -$298 ﹤0.01% 5084
2024
Q4 		$954 Sell
212
-57,018
-100% -$289K ﹤0.01% 5138
2024
Q3 		$159K Buy
57,230
+7,178
+14% +$22.1K ﹤0.01% 4412
2024
Q2 		$171K Buy
50,052
+33,710
+206% +$155K ﹤0.01% 3656
2024
Q1 		$88.6K Buy
16,342
+8,760
+116% +$62.9K ﹤0.01% 4475
2023
Q4 		$41.1K Buy
+7,582
New +$35.8K ﹤0.01% 4804

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Barclays's SGMT Position: Q2 2026 in Review

Barclays increased its Sagimet Biosciences (SGMT) stake by 731% in Q2 2026, buying an estimated $1.36M and bringing the position to 227,931 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

Barclays first reported a position in SGMT in Q4 2023 and has held it in 10 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Barclays held 227,931 shares of Sagimet Biosciences worth $1.76M as of Q2 2026.
  • Barclays bought 200,502 Sagimet Biosciences shares in Q2 2026, an estimated $1.36M.
  • Sagimet Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2425 holding.
  • Barclays first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 10 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.